1. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.
2. National guidelines for diagnosis and treatment of hypertension (4th revision). Sistemye Gipertenzii 2010; (3) : 5-26. Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5-26.
3. Mancia G. Tolerability and safety of telmisartan as monotherapy or combined with hydrochlorothiazide compared with placebo. Am J Hypertens 2002; 15 (Supp 1): A54
4. Chazova I.E., Ratova L.G. The first generation sartans: Is there a future? Sistemnye Gipertenzii 2010; (4): 5–9. Russian (Чазова И.Е., Ратова Л.Г . Первое поколение сартанов: есть ли перспективы? Системные Гипертензии 2010; (4): 25-28).
5. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res. 2000 Jul-Aug;28(4):149-67.
6. The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
7. The TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008, 372: 1174–83.
8. Barnett AH, Bain SC, Bouter P et al. Diabetics exposed to telmisartan and enalapril study group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351 (19): 1952–61.
9. Galle J, Schwedhelm E, Pinnetti S et al. VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23 (10): 3174–83.
10. Prasad B, Ravi N, Asma K et al. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 2009; 5: 129–40.
11. Makino H, Haneda M, Babazono T et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy – rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin ii receptor blocker , telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) Study. J Int Med Res 2005; 33: 677–86.
12. Kurtz T ., Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009;32(10): 826–34.
